ClinicalTrials.gg
RecruitingNCT07640451Updated Aug 18, 2026

A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of HRS-9821 Inhalation Suspension and HRS-9821 Placebo Inhalation Suspension in COPD, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
180th of 286
90 · median 155
Started
2026
with 33 others
Phase 2
33 of 404
13 open now
Primary completion
2026-10
later than 48 of 124 live
Registered
384th of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 180th largest by planned enrollment of the 286 interventional ones that give a count, is one of 34 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 48 of the 124 other live ones, and was the 384th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

102 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 40 years old and \< 80 years old, male or female.
  2. Meet the weight standard.
  3. Smoking history ≥ 10 pack-years.
  4. has been diagnosed ≥ 1 year.
  5. 4 weeks before screening, the background treatment for COPD was stable.
  6. /FVC \< 0.7, 30% ≤ FEV1 ≤ 80%.
  7. mMRC score ≥ 2.
  8. The inspection and medication can be completed as required.
  9. Non-pregnant and breastfeeding state.
  10. Able and willing to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening .
  2. Other pulmonary diseases that may affect the efficacy evaluation of this study.
  3. Concurrent diseases other than COPD that may affect lung function.
  4. History of asthma.
  5. Pulmonary heart disease requiring clinical intervention, or moderate to severe pulmonary hypertension.
  6. Malignant tumors within 5 years.
  7. Uncontrolled severe cardiovascular and cerebrovascular diseases within 1 year.
  8. Unstable diseases.
  9. Acute exacerbation of COPD within 12 weeks, hospitalization for COPD or pneumonia within 6 months.
  10. Infection in the lungs or other parts occurs within 16 weeks and requires treatment.
  11. .
  12. Uncontrolled hypertension.
  13. Lung resection, surgical lung volume reduction or endoscopic treatment for COPD.
  14. Undergone major surgery or planned surgery within 14 months.
  15. Abnormal chest images have clinical significance.
  16. Tuberculosis infection requiring treatment within 16 to 12 months.
  17. Virological test result was positive.
  18. Laboratory blood tests and were significantly abnormal.
  19. Requires oxygen inhalation or intermittent oxygen inhalation therapy.
  20. Hypercapnia, using or requiring long-term use of any non-invasive positive pressure ventilation device.
  21. Biological agents that may have therapeutic effects on the studied disease have been used within 12 weeks or within 5 half-lives of the drug.
  22. Vaccination, theophylline or drugs within 4 weeks.
  23. Having participated in other clinical studies within 4 weeks and used research drugs or medical devices containing active ingredients, or still within 5 half-lives of the research drug.
  24. Systemic , immunosuppressants, and oral Roflumilast within 12 weeks.
  25. Undergoing or planning rehabilitation treatment for pulmonary rehabilitation.
  26. Non-selective β blockers within 1 week.
  27. Overly potent/moderately potent drugs that inhibit or induce the liver drug-metabolizing enzyme within 14 days.
  28. Allergic to the research drug or salbutamol or .
  29. Has been used HRS-9821.
  30. Drug abuse and alcohol abuse within 1 year.
  31. Pregnant or lactating period or planning to be pregnant or lactating.
  32. The researchers judged that there were other unsuitable circumstances.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HRS-9821 Group - Dose 1

    HRS-9821 Inhalation Suspension, Dose 1.

    Drug: HRS-9821 Inhalation Suspension

  • Experimental
    HRS-9821 Group - Dose 2

    HRS-9821 Inhalation Suspension, Dose 2.

    Drug: HRS-9821 Inhalation Suspension

  • Placebo comparator
    HRS-9821 Placebo Group - Dose 1

    HRS-9821 Placebo Inhalation Suspension, Dose 1.

    Drug: HRS-9821 Placebo Inhalation Suspension

  • Placebo comparator
    HRS-9821 Placebo Group - Dose 2

    HRS-9821 Placebo Inhalation Suspension, Dose 2.

    Drug: HRS-9821 Placebo Inhalation Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in peak FEV1 (forced expiratory volume in one second) after 28 days of treatment.

    Time frame: From baseline to 28 days after treatment.

Secondary outcomes

  1. Changes in FEV1 area under the curve versus time from 0 to 12 hours (AUC0-12h) and 0 to 4 hours (AUC0-4h) after 1, 14 and 28 days of treatment.

    Time frame: During 28 days of treatment.

  2. Changes in peak FEV1 after 1 and 14 days of treatment.

    Time frame: After 1 and 14 days of treatment.

  3. Changes in trough FEV1 after 1, 14 and 28 days of treatment.

    Time frame: After 1, 14 and 28 days of treatment.

  4. Changes in FVC (forced vital capacity) during 28 days of treatment.

    Time frame: During 28 days of treatment.

  5. Changes of in SGRQ (St. George's Respiratory Questionnaire), CAT (COPD Assessment Test), mMRC (modified Medical Research Council) score during 28 days of treatment.

    Time frame: During 28 days of treatment.

  6. The use of SABA (Short-Acting Beta₂ Agonist) during 28 days of treatment.

    Time frame: During 28 days of treatment.

Other outcomes

  1. Incidence and severity of adverse events (AEs) during the 7-week study period.

    Safety outcome.

    Time frame: During the 7-week study period.

  2. Plasma concentration of HRS-9821 after 1, 14 and 28 days of treatment.

    Pharmacokinetic outcome.

    Time frame: After 1, 14 and 28 days of treatment.

  3. Peak concentration after 1, 14 and 28 days of treatment.

    Pharmacokinetic outcome.

    Time frame: After 1, 14 and 28 days of treatment.

  4. Trough concentration after 1, 14 and 28 days of treatment.

    Pharmacokinetic outcome.

    Time frame: After 1, 14 and 28 days of treatment.

  5. Population Typical Clearance (CL/F) after 1, 14 and 28 days of treatment.

    Pharmacokinetic outcome, population pharmacokinetic (PopPK) parameters.

    Time frame: After 1, 14 and 28 days of treatment.

  6. Population Typical Apparent Volume of Distribution (Vd/F) after 1, 14 and 28 days of treatment.

    Pharmacokinetic outcome, population pharmacokinetic (PopPK) parameters.

    Time frame: After 1, 14 and 28 days of treatment.

  7. Changes in maximum mid-expiratory flow (MMEF) after 1, 14 and 28 days of treatment.

    Exploratory outcome.

    Time frame: During 28 days of treatment.

  8. Incidence of moderate/severe acute exacerbation of COPD (AECOPD) during 4 weeks of treatment.

    Exploratory outcome.

    Time frame: During 4 weeks of treatment.

  9. Changes in peripheral blood biomarkers (EOS, Neut, IL-6, IL-8, CRP, etc.) during 4 weeks of treatment.

    Exploratory outcome.

    Time frame: During 4 weeks of treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 3 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 10, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Nov 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640451
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jul 20, 2026
Primary completion
Oct 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 18, 2026

Study contacts

Si Chen, M.M
Contact
si.chen.sc96@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9821

Start the discussion